**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 68615

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy**

Rubin SJS *et al*. IBD exacerbation following ICI treatment

Samuel J S Rubin, Tatiana Balabanis, John Gubatan, Aida Habtezion

**Samuel J S Rubin, Tatiana Balabanis, John Gubatan, Aida Habtezion,** Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States

**Author contributions:** Rubin SJS, Gubatan J and Habtezion A helped plan the study, interpret data, and draft the manuscript. Rubin SJS, Balabanis T, Gubatan J and Habtezion A interpreted data; Balabanis T collected data; all authors approved the final draft submitted.

**Supported by** the Stanford Medical Scholars Fellowship Program to Rubin SJS.

**Corresponding author: Samuel J S Rubin, PhD, Postdoctoral Fellow,** Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Alway Building, Room M211, 300 Pasteur Drive, Stanford, CA 94305, United States. yrubin@stanford.edu

**Received:** May 28, 2021

**Revised:** July 19, 2021

**Accepted:** January 11, 2022

**Published online:** February 26, 2022

**Abstract**

BACKGROUND

Colitis is a known potential toxicity of immune checkpoint inhibitors (ICIs). Studies evaluating the risk of disease exacerbation following ICI treatment in patients with pre-existing inflammatory bowel disease (IBD) are limited.

AIM

To assess the clinical characteristics of IBD patients treated with ICIs and determine prevalence of subsequent IBD exacerbations.

METHODS

We conducted a retrospective cohort study of all patients in the Stanford Research Repository database with pre-existing IBD who were exposed to ICIs.

RESULTS

The prevalence of IBD exacerbation following ICI was 36.8% amongst 19 patients meeting inclusion criteria. Patients with exacerbations had more gastrointestinal-related hospitalizations (4 of 7) than patients without exacerbations (0 of 12; *P* = 0.0090).

CONCLUSION

The prevalence of IBD exacerbations following ICI was higher than reported rates of ICI-induced colitis and diarrhea in the general population and was associated with hospitalization.

**Key Words:** Inflammatory bowel disease; Immune checkpoint inhibitors; Immunotherapy; Malignancy

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Rubin SJS, Balabanis T, Gubatan J, Habtezion A. Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy. *World J Clin Cases* 2022; 10(6): 1787-1794

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i6/1787.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i6.1787

**Core Tip:** Immune checkpoint inhibitor (ICI)-mediated colitis is increasingly recognized as a complication of ICI therapy. The clinical outcomes of ICI therapy on underlying inflammatory bowel disease (IBD) in patients with malignancy is poorly understood. In this retrospective cohort study of IBD patients treated with ICIs for malignancy, we demonstrate that the prevalence of IBD exacerbation following ICI therapy was higher than reported ICI-induced colitis and diarrhea in the general population. ICI use among patients with IBD who had a disease exacerbation was also associated with increased rates of hospitalization.

**INTRODUCTION**

Immune checkpoint inhibitor (ICI) monoclonal antibodies block surface receptors on leukocytes, triggering profound immune responses. Use of ICIs for cancer treatment is increasing; the number of Food and Drug Administration-approved indications is growing, with additional ICIs in development[1]. Immune-related adverse events (irAEs) and disease exacerbations following ICIs have been documented for pre-existing inflammatory diseases and are typically managed with prompt steroids, immunomodulators, and/or tumor necrosis factor inhibitors[2,3]. Thus, clinical benefit of ICIs for malignancy in patients with certain pre-existing conditions may be limited due to serious risks.

Gastrointestinal (GI) irAEs, including diarrhea and ICI-mediated colitis (IMC), are amongst the most common ICI-associated irAEs[4]. In the general population treated with ICIs, the incidence of diarrhea was 12.1%-13.7% for anti-programmed cell death protein (PD)-1, 30.2%-35.4% for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), and 9.1%-10.6% for combination ICIs, while the incidence of colitis was 0.7%-1.6% for anti-PD-1, 5.7%-9.1% for anti-CTLA-4, and 13.6% for combination ICIs[1]. Use of anti-CTLA-4 ICIs is considered to increase the risk of IMC[5,6]. Recent reports suggest that the incidence of GI irAEs following ICI administration in patients with pre-existing inflammatory bowel disease (IBD) may be higher than the general population[7-9]. While these studies provided insight into IBD exacerbation rates following ICI therapy in small cohorts at a limited number of study centers, data on patient comorbidities, medications, and baseline IBD activity were lacking and might affect irAE occurrence and recognition. Understanding the prevalence, detailed clinical characteristics and outcomes of ICI-induced IBD exacerbation in broader patient populations remains an ongoing challenge. We aimed to assess the clinical characteristics of IBD patients treated with ICIs at our previously unreported center and determine IBD exacerbation prevalence in this novel population.

**MATERIALS AND METHODS**

We performed a retrospective cohort study of all IBD patients exposed to ICIs from 2000 through August 13, 2020 at Stanford Healthcare using the Stanford Research Repository Tool database, as approved by the Stanford Institutional Review Board. Patients were screened by International Classification of Diseases codes (K50, CD; K51, ulcerative colitis; K52, other unspecified noninfective gastroenteritis and colitis; 555, regional enteritis; 556, other ulcerative colitis) and ICI (ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, or cemiplimab). Pre-existing IBD diagnosis and subsequent ICI administration were confirmed by chart review. All subjects with these inclusion criteria were reported. Patients whose IBD diagnosis did not predate ICI were excluded. Demographics, comorbidities, medications, disease phenotypes, and clinical outcomes were collected by chart review. The primary outcome was prevalence of IBD exacerbation following ICI, as defined by new onset bloody stool, rectal bleeding, diarrhea, and/or increased bowel movements. No patients with IBD exacerbations had documented GI infections following ICI use, as determined by GI polymerase chain reaction panel, *Clostridium difficile* toxin testing, and/or stool culture. One patient with IBD exacerbation had chronic hepatitis C virus infection, and another had a postoperative wound infection. Missing data is indicated in table footnotes. No data was imputed. Statistical analyses were performed in Microsoft Excel (16.43), GraphPad Prism (8.4.3) and R (3.3.2).

**RESULTS**

Nineteen patients met inclusion criteria of pre-existing IBD and subsequent ICI therapy. Four had Crohn’s disease (CD), fourteen ulcerative colitis (UC), and one indeterminate IBD (Table 1). The median age of patients with CD was 63 [interquartile range (IQR), 4] and UC was 69 (IQR, 12.5). Patients were predominantly of male sex and white race. No patients had extraintestinal IBD manifestations nor pediatric onset IBD; the median age of onset was 56 (IQR, 0) for CD and 39.5 (IQR, 32.8) for UC.

All patients had controlled asymptomatic IBD when beginning ICI therapy, after which seven developed GI irAEs consistent with IBD exacerbation (Tables 2 and 3). Median length of ICI use was 12 mo (IQR, 10) and 6.5 mo (IQR, 9.3) in patients with and without exacerbations, respectively (*P* = 0.3685; Table 3). Median follow-up time was 435 d (IQR, 306) and 572 d (IQR, 450) from beginning ICI therapy for patients with and without exacerbations, respectively (*P* = 0.4824). Demographics, comorbidities, IBD characteristics (location, behavior, *etc.*), and medications were evaluated and not associated with ICI-induced IBD exacerbation (Table 2).

Four of seven patients with IBD exacerbations required GI-related hospitalization following ICI treatment, compared to none of 12 patients without exacerbations (57.1% *vs* 0%; *P* = 0.0090); two patients with exacerbations required GI surgery (Table 3). IBD medical therapy following ICI was not significantly different between patients with and without IBD exacerbations (Table 3). Importantly, no patients with IBD exacerbations had documented GI infections following ICI, consistent with exacerbation due to flare of underlying IBD. One patient who had an exacerbation after ICI underwent flexible sigmoidoscopy, demonstrating circumferential colitis from the anus to distal sigmoid colon, consistent with a flare of pre-existing left-sided UC.

**DISCUSSION**

Recent reports suggest higher incidence of GI irAEs in patients with pre-existing IBD following ICI therapy (28%-41%) compared to the general population (diarrhea: 9.1%-35.4%; colitis: 0.7%-13.6%)[1,7-9]. We observed GI irAEs consistent with IBD exacerbations in 36.8% of IBD patients treated with ICIs in a novel patient population, which parallels this emerging pattern.

Patients with IBD exacerbations experienced more GI-related hospitalizations, half accompanied by surgery. There was no association between ICI type and IBD exacerbation. Although only three patients were on antibodies directed against CTLA-4, this is consistent with another recent report[9]. We found no associations between IBD exacerbation and non-IBD medications, including proton pump inhibitors, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, antidiabetic agents, antihypertensive agents, and others analyzed (Table 2).

Our study adds to developing literature on ICIs in IBD, providing detailed data on prevalence of IBD exacerbation and outcomes in this vulnerable population. Importantly, while GI symptoms are common amongst IBD and cancer patients and could resemble GI irAEs, all patients had controlled asymptomatic IBD prior to ICI use, and no patients with subsequent IBD exacerbations had GI infections. Another strength of our study was inclusion of additional clinical characteristics, including medications, comorbidities, race, and ethnicity, relative to previous studies. Cohort size was limited due to the single-center nature of our study and the rarity of IBD preceding ICI therapy.

**CONCLUSION**

In conclusion, our data highlight that relative to non-IBD patients, those with pre-existing IBD are a vulnerable population at increased risk of ICI-induced IBD flare. These findings demonstrate the importance of closely monitoring ICIs in the setting of IBD and the need for larger prospective studies to define factors associated with ICI-induced flare in IBD patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Colitis and diarrhea are immune-related adverse events associated with immune checkpoint inhibitor (ICI) therapy.

***Research motivation***

The risk of inflammatory bowel disease (IBD) exacerbation following ICI treatment of malignancy in these patients is poorly understood.

***Research objectives***

We aimed to understand clinical characteristics of IBD patients treated with ICIs for malignancy and their clinical outcomes.

***Research methods***

We conducted a retrospective cohort study of all IBD patients treated with ICIs for malignancy and Stanford Healthcare.

***Research results***

The prevalence of IBD exacerbation amongst patients treated with ICI therapy for malignancy was 36.8%. Individuals with exacerbation of pre-existing IBD had more gastrointestinal-related hospitalizations.

***Research conclusions***

IBD exacerbation amongst patients treated with ICIs for malignancy was higher than reported rates of colitis and diarrhea in the general population treated with ICIs for malignancy.

***Research perspectives***

IBD patients are vulnerable to disease exacerbation when treated with ICIs for malignancy, and close monitoring should be implemented. Further studies will aim to better understand what factors modulate risk of IBD exacerbation in patients following ICI administration.

**ACKNOWLEDGEMENTS**

We thank Dr. Alexa R. Weingarden, MD, PhD for helpful discussions, critiques, and feedback on the study design and manuscript.

**REFERENCES**

1 **Bellaguarda E**, Hanauer S. Checkpoint Inhibitor-Induced Colitis. *Am J Gastroenterol* 2020; **115**: 202-210 [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497]

2 **Coureau M**, Meert AP, Berghmans T, Grigoriu B. Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders. *Front Med (Lausanne)* 2020; **7**: 137 [PMID: 32457912 DOI: 10.3389/fmed.2020.00137]

3 **Tison A**, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. *Arthritis Rheumatol* 2019; **71**: 2100-2111 [PMID: 31379105 DOI: 10.1002/art.41068]

4 **Brahmer JR**, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2018; **36**: 1714-1768 [PMID: 29442540 DOI: 10.1200/JCO.2017.77.6385]

5 **Yao J**, Li M, Zhang H, Ge Y, Weygant N, An G. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. *Int Immunopharmacol* 2020; **87**: 106770 [PMID: 32702598 DOI: 10.1016/j.intimp.2020.106770]

6 **Johnson DB**, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. *JAMA Oncol* 2016; **2**: 234-240 [PMID: 26633184 DOI: 10.1001/jamaoncol.2015.4368]

7 **Grover S**, Ruan AB, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, Buchbinder EI, Ott PA, Kehl KL, Awad MM, Hodi FS, Rahma OE. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. *JCO Oncol Pract* 2020; **16**: e933-e942 [PMID: 32401685 DOI: 10.1200/JOP.19.00672]

8 **Braga Neto MB**, Ramos GP, Loftus EV Jr, Faubion WA, Raffals LE. Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series. *Clin Gastroenterol Hepatol* 2021; **19**: 1285-1287.e1 [PMID: 32565289 DOI: 10.1016/j.cgh.2020.06.031]

9 **Abu-Sbeih H**, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. *J Clin Oncol* 2020; **38**: 576-583 [PMID: 31800340 DOI: 10.1200/JCO.19.01674]

**Footnotes**

**Institutional review board statement:** The study is approved by the Stanford Institutional Review Board (57160).

**Informed consent statement:** Because of the retrospective and anonymous character of this study, the need for informed consent was waived by the institutional review board.

**Conflict-of-interest statement:** All authors declare no conflicts of interest.

**Data sharing statement:** The full data underlying this article cannot be shared publicly due to privacy of the individuals that participated in the study. The de-identified data will be shared on reasonable request to the corresponding authors.

**STROBE statement:** Authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 1, 2021

**First decision:** July 14, 2021

**Article in press:** January 11, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Sitkin S **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ

**Table 1 Baseline demographics and inflammatory bowel disease characteristics stratified by inflammatory bowel disease diagnosis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Crohn's disease** | **Ulcerative colitis** | **Indeterminate IBD** |
| ***n* = 4** | ***n* = 14** | ***n* = 1** |
| Demographics |  |  |  |
| Age at first ICI use, yr, median, IQR | 63, 4 | 69, 12.5 | 60, 0 |
| Female sex, *n* (%) | 2 (50.0) | 2 (14.3) | 0 (0) |
| White race, *n* (%) | 3 (75.0) | 11 (78.6) | 1 (100) |
| Black race, *n* (%) | 1 (25.0) | 1 (7.1) | 0 (0) |
| Asian race, *n* (%) | 0 (0) | 1 (7.1) | 0 (0) |
| Other race, *n* (%) | 0 (0) | 1 (7.1) | 0 (0) |
| Non-Hispanic ethnicity, *n* (%) | 4 (100) | 12 (85.7) | 1 (100) |
| Hispanic/Latino ethnicity, *n* (%) | 0 (0) | 2 (14.3) | 0 (0) |
| Never smoker, *n* (%) | 2 (50.0) | 5 (35.7) | 0 (0) |
| Former smoker, *n* (%) | 2 (50.0) | 9 (64.3) | 1 (100) |
| Body mass index, median, IQR | 21.6, 1.7 | 25.5, 6.1 | 24.1, 0 |
| IBD characteristics |  |  |  |
| Age at IBD onset, yr, median, IQR1 | 56, 0 | 39.5, 32.8 | 54, 0 |
| IBD duration, yr, median, IQR1 | 7, 1 | 20, 29.25 | 6, 0 |
| Disease location, *n* (%) | L1: 1 (25.0) | E1: 1 (7.1) | - |
| L2: 1 (25.0) | E2: 4 (28.6) | - |
| L3: 2 (50.0) | E3: 7 (50.0) | - |
| - | Unknown: 2 (14.3) | - |
| Disease behavior, *n* (%) | B1: 2 (50.0) | - | - |
| B2: 1 (25.0) | - | - |
| B3: 0 (0) | - | - |
| Unknown: 1 (25.0) | - | - |
| Perianal disease, *n* (%) | 0 (0) | - | - |
| Extra-intestinal manifestations, *n* (%) | 0 (0) | 0 (0) | 0 (0) |

1Unknown for 2 CD and 4 UC patients because date of IBD onset was not available.

Disease location and behavior were categorized using the Montreal classification: Location (L): L1, ileal disease; L2, colonic disease; L3, ileocolonic disease; Behavior (B): B1, inflammatory phenotype; B2, obstructive/stricturing phenotype; B3, penetrating/fistulizing phenotype; Extent (E): E1, proctitis; E2, left-sided colitis; E3, extensive/pan colitis. IQR: Interquartile range; IBD: Inflammatory bowel disease; ICI: Immune checkpoint inhibitor.

**Table 2 All baseline clinical characteristics stratified by prevalence of inflammatory bowel disease exacerbation**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Exacerbation** | **No exacerbation** | ***P* value1** |
| ***n* = 7** | ***n* = 12** |
| Demographics |  |  |  |
| Female sex, *n* (%) | 0 (0) | 4 (33.3) | 0.2451 |
| Age at first ICI use, yr, median, IQR | 60, 12.5 | 66, 9.3 | 0.6055 |
| White race, *n* (%) | 4 (57.1) | 11 (91.7) | 0.1174 |
| Black race, *n* (%) | 1 (14.3) | 1 (8.3) | 1.0000 |
| Asian race, *n* (%) | 1 (14.3) | 0 (0) | 0.3684 |
| Other race, *n* (%) | 1 (14.3) | 0 (0) | 0.3684 |
| Non-Hispanic ethnicity, *n* (%) | 5 (71.4) | 12 (100) | 0.1228 |
| Hispanic/Latino ethnicity, *n* (%) | 2 (28.6) | 0 (0) | 0.1228 |
| Former smoker, *n* (%) | 3 (42.9) | 9 (75.0) | 0.3261 |
| Body mass index, median, IQR | 24.3, 1.8 | 25.2 (6.7) | 0.9018 |
| Co-morbidities |  |  |  |
| Hypertension, *n* (%) | 1 (14.3) | 6 (50.0) | 0.1733 |
| Hyperlipidemia, *n* (%) | 3 (42.9) | 6 (50.0) | 1.0000 |
| Heart failure, *n* (%) | 0 (0) | 3 (25.0) | 0.2632 |
| Coronary artery disease, *n* (%) | 0 (0) | 2 (16.7) | 0.5088 |
| Chronic kidney disease, *n* (%) | 0 (0) | 2 (16.7) | 0.5088 |
| Diabetes mellitus, *n* (%) | 2 (28.6) | 1 (8.3) | 0.5232 |
| Gastroesophageal reflux disease, *n* (%) | 1 (14.3) | 1 (8.3) | 1.0000 |
| Asthma, *n* (%) | 0 (0) | 2 (16.7) | 0.5088 |
| Chronic obstructive pulmonary disease, *n* (%) | 1 (14.3) | 1 (8.3) | 1.0000 |
| IBD characteristics |  |  |  |
| Crohn's disease, *n* (%) | 0 (0) | 4 (33.3) | 0.2451 |
| Ulcerative colitis, *n* (%) | 6 (85.7) | 8 (66.7) | 0.6027 |
| Indeterminate IBD, *n* (%) | 1 (14.3) | 0 (0) | 0.3684 |
| Age at IBD onset, yr, median, IQR2 | 47, 28.3 | 56, 24.5 | 0.9668 |
| IBD duration, yr, median, IQR2 | 11.5, 19.75 | 20, 24 | 0.9184 |
| History of GI surgery before ICI use, *n* (%) | 2 (28.6) | 5 (41.7) | 0.6562 |
| Latest known disease state before ICI use, *n* (%) | Active: 0 (0) | Active: 0 (0) | 1.0000 |
| Inactive: 5 (71.4) | Inactive: 10 (83.3) | 0.6027 |
| Unknown: 2 (28.6) | Unknown: 2 (16.7) | 0.6027 |
| Latest available 25 (OH) D before ICI use, ng/mL, median, IQR3 | 38.9, 11.2 | 29.0, 9.5 | 0.8857 |
| GI medications at start of ICI use, *n* (%) |  |  |  |
| Aminosalicylate | 3 (42.9) | 3 (25.0) | 0.6169 |
| Glucocorticoid | 1 (14.3) | 2 (16.7) | 1.0000 |
| Cholecalciferol (vitamin D3) | 3 (42.9) | 3 (25.0) | 0.6169 |
| Laxative (PEG, senna glycoside, docusate) | 3 (42.9) | 3 (25.0) | 0.6169 |
| Anti-diarrheal (diphenoxylate-atropine, loperamide) | 1 (14.3) | 3 (25.0) | 1.0000 |
| TNF inhibitor | 0 (0) | 1 (8.3) | 1.0000 |
| Mercaptopurine | 1 (14.3) | 0 (0) | 0.3684 |
| Other medications at start of ICI use, *n* (%) |  |  |  |
| Oral antibiotics | 0 (0) | 2 (16.7) | 0.5088 |
| Proton pump inhibitor | 3 (42.9) | 2 (16.7) | 0.3047 |
| Famotidine | 0 (0) | 2 (16.7) | 0.5088 |
| Metformin | 1 (14.3) | 0 (0) | 0.3684 |
| Insulin secretagogue | 0 (0) | 1 (8.3) | 1.0000 |
| Insulin | 1 (14.3) | 1 (8.3) | 1.0000 |
| Benzodiazepine | 2 (28.6) | 4 (33.3) | 1.0000 |
| Selective serotonin reuptake inhibitors | 1 (14.3) | 2 (16.7) | 1.0000 |
| Diuretic | 0 (0) | 4 (33.3) | 0.2451 |
| ACE inhibitor or angiotensin receptor blocker | 3 (42.9) | 5 (41.7) | 1.0000 |
| HMA-CoA reductase inhibitor | 4 (57.1) | 6 (50.0) | 1.0000 |
| Anticoagulant or antiplatelet | 1 (14.3) | 4 (33.3) | 0.6027 |
| Nonsteroidal anti-inflammatory drug | 3 (42.9) | 3 (25.0) | 0.6169 |
| Donezepil | 1 (14.3) | 1 (8.3) | 1.0000 |
| Glucosamine | 1 (14.3) | 1 (8.3) | 1.0000 |
| Ondansetron | 2 (28.6) | 3 (25.0) | 1.0000 |
| Chemotherapeutic kinase inhibitor | 1 (14.3) | 0 (0) | 0.3684 |
| Cancer characteristics and management |  |  |  |
| Primary cancer origin, *n* (%) |  |  |  |
| Bladder | 0 (0) | 5 (41.7) | 0.1060 |
| Melanoma | 3 (42.9) | 2 (16.7) | 0.3047 |
| Lung | 2 (28.6) | 4 (33.3) | 1.0000 |
| GI | 1 (14.3) | 1 (8.3) | 1.0000 |
| Other | 1 (14.3) | 3 (25.0) | 1.0000 |
| Radiation therapy for cancer, *n* (%) | 5 (71.4) | 9 (75.0) | 1.0000 |
| Checkpoint inhibitor, *n* (%) |  |  |  |
| Ipilimumab | 2 (28.6) | 1 (8.3) | 0.5232 |
| Nivolumab | 2 (28.6) | 2 (16.7) | 0.6027 |
| Pembrolizumab | 4 (57.1) | 8 (66.7) | 1.0000 |
| Atezolizumab | 0 (0) | 1 (8.3) | 1.0000 |
| Avelumab | 0 (0) | 0 (0) | 1.0000 |
| Durvalumab | 0 (0) | 1 (8.3) | 1.0000 |
| Cemiplimab | 0 (0) | 0 (0) | 1.0000 |
| Any anti-PD-1 or -PD-L1 | 6 (85.7) | 12 (100) | 0.3684 |
| Combination anti-CTLA-4 and -PD-1/PD-L1 | 1 (14.3) | 1 (8.3) | 1.0000 |

1*P*-values from Fisher's exact test for categorical variables or Mann-Whitney *U* test for continuous variables.

2Unknown for 1 patient with and 5 patients without immune checkpoint inhibitor (ICI)-attributed inflammatory bowel disease (IBD) exacerbations because date of IBD onset was not available.

3Unknown for 3 patients with and 8 patients without ICI-attributed IBD exacerbations.

IQR: Interquartile range; IBD: Inflammatory bowel disease; ICI: Immune checkpoint inhibitor; GI: Gastrointestinal; PEG: Polyethylene glycol; ACE: Angiotensin converting enzyme; HMA-CoA: Hydroxymethylglutaryl-coenzyme A; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; CTLA-4: Cytotoxic T-lymphocyte antigen 4.

**Table 3 Inflammatory bowel disease management and clinical outcomes following immune checkpoint inhibitor treatment stratified by prevalence of inflammatory bowel disease exacerbation**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Exacerbation** | **No exacerbation** | ***P* value1** |
| ***n* = 7** | ***n* = 12** |
| Follow up time, d, median, IQR | 435, 306 | 572, 450 | 0.4824 |
| Length of ICI use, mo, median, IQR | 12, 10 | 6.5, 9.3 | 0.3685 |
| Reason for ICI discontinuation, *n* (%) |  |  |  |
| Cancer remission | 1 (14.3) | 1 (8.3) | 1.0000 |
| Cancer non-response | 0 (0) | 2 (16.7) | 0.5088 |
| Side effect(s) | 1 (14.3) | 3 (25.0) | 1.0000 |
| Patient preference | 0 (0) | 1 (8.3) | 1.0000 |
| Deceased | 1 (14.3) | 2 (16.7) | 1.0000 |
| Unknown | 0 (0) | 1 (8.3) | 1.0000 |
| Not discontinued | 4 (57.1) | 2 (16.7) | 0.1287 |
| GI-related hospitalization, *n* (%) | 4 (57.1) | 0 (0) | 0.0090 |
| GI-related surgery, *n* (%) | 2 (28.6) | 0 (0) | 0.1228 |
| IBD medications used after ICI initiation, *n* (%) |  |  |  |
| Aminosalicylates | 4 (57.1) | 4 (33.3) | 0.3765 |
| Glucocorticoids | 3 (42.9) | 4 (33.3) | 1.0000 |
| TNF inhibitor | 2 (28.6) | 1 (8.3) | 0.5232 |
| Mercaptopurine | 1 (14.3) | 0 (0) | 0.3684 |
| None | 2 (28.6) | 5 (41.7) | 0.6562 |
| Deceased, *n* (%) | 1 (14.3) | 4 (33.3) | 0.6027 |

1*P*-values from Fisher's exact test.

IQR: Interquartile range; IBD: Inflammatory bowel disease; ICI: Immune checkpoint inhibitor; GI: Gastrointestinal; TNF: Tumor necrosis factor.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**